Healthcare provider profile · identity verified

Michael J Citrin, MD

Family Practice · HIGHLANDS RANCH, CO · NPI 1386756575

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	623	183
Lisinopril	Lisinopril	342	99
Tamsulosin Hcl	Tamsulosin Hcl	300	93
Rosuvastatin Calcium	Rosuvastatin Calcium	290	104
Losartan Potassium	Losartan Potassium	238	72
Simvastatin	Simvastatin	229	66
Amlodipine Besylate	Amlodipine Besylate	226	71
Levothyroxine Sodium	Levothyroxine Sodium	211	61
Omeprazole	Omeprazole	210	73
Metformin Hcl	Metformin Hcl	158	49
Allopurinol	Allopurinol	120	36
Pradaxa	Dabigatran Etexilate Mesylate	114	42
Metoprolol Tartrate	Metoprolol Tartrate	106	32
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	100	30
Trazodone Hcl	Trazodone Hcl	97	34
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	85	27
Finasteride	Finasteride	83	27
Alendronate Sodium	Alendronate Sodium	81	35
Gabapentin	Gabapentin	76	28
Atenolol	Atenolol	72	21
Arexvy	Rsvpref3 Antigen/As01e/Pf	68	68
Metformin Hcl Er	Metformin Hcl	61	20
Pantoprazole Sodium	Pantoprazole Sodium	57	21
Glipizide	Glipizide	55	17
Albuterol Sulfate Hfa	Albuterol Sulfate	54	25
Famotidine	Famotidine	53	17
Sertraline Hcl	Sertraline Hcl	53	17
Hydrochlorothiazide	Hydrochlorothiazide	52	17
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	46	46
Jardiance	Empagliflozin	45	14
Citalopram Hbr	Citalopram Hydrobromide	43	13
Duloxetine Hcl	Duloxetine Hcl	43	15
Ezetimibe	Ezetimibe	42	15
Warfarin Sodium	Warfarin Sodium	34	suppressed
Bupropion Xl	Bupropion Hcl	33	suppressed
Furosemide	Furosemide	33	14
Meloxicam	Meloxicam	32	19
Oxycodone Hcl	Oxycodone Hcl	31	11
Acyclovir	Acyclovir	30	12
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Alvesco	Ciclesonide	28	12
Ciclopirox	Ciclopirox	28	suppressed
Humulin N	Insulin Nph Human Isophane	28	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	28	suppressed
Metoprolol Succinate	Metoprolol Succinate	28	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	28	27
Fluticasone Propionate	Fluticasone Propionate	27	suppressed
Potassium Chloride	Potassium Chloride	26	12
Tramadol Hcl	Tramadol Hcl	26	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	25	suppressed
Pravastatin Sodium	Pravastatin Sodium	24	suppressed
Carvedilol	Carvedilol	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Spiriva Respimat	Tiotropium Bromide	20	suppressed
Ondansetron Odt	Ondansetron	19	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	17	suppressed
Celecoxib	Celecoxib	16	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Ozempic	Semaglutide	16	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	15	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	13
Clopidogrel	Clopidogrel Bisulfate	14	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	14	14
Hydromorphone Hcl	Hydromorphone Hcl	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Repatha Sureclick	Evolocumab	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Colchicine	Colchicine	12	suppressed
Doxepin Hcl	Doxepin Hcl	12	suppressed
Trospium Chloride	Trospium Chloride	12	suppressed
Trulance	Plecanatide	12	suppressed
Clonazepam	Clonazepam	11	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error